A Fecal-Based Therapy To Prevent Recurrent C. diff Infection Is The First FDA-Approved Microbiome Therapeutic
The Food and Drug Administration recently approved a fecal-based therapy to prevent recurrent Clostridioides difficile infection. Rebyota is a drug that is approved for the prevention of recurring C. dificile infection also known as CDI in individuals of 18 year old and above.
